$1.69 Billion is the total value of Sofinnova Investments, Inc.'s 70 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Merck & Co Inccall | $45,066,000 | – | 600,000 | +100.0% | 2.67% | – | |
| ABBV | New | Abbvie Inc | $29,405,000 | – | 272,600 | +100.0% | 1.74% | – |
| New | Bristol-Myers Squibb Cocall | $23,668,000 | – | 400,000 | +100.0% | 1.40% | – | |
| BPMC | New | Blueprint Medicines Corp | $18,697,000 | – | 181,860 | +100.0% | 1.11% | – |
| New | Regeneron Pharmaceuticalsput | $18,155,000 | – | 30,000 | +100.0% | 1.08% | – | |
| New | United Therapeutics Corpput | $17,443,000 | – | 94,500 | +100.0% | 1.03% | – | |
| HZNP | New | Horizon Therapeutics Pub L | $17,251,000 | – | 157,487 | +100.0% | 1.02% | – |
| ZTS | New | Zoetis Inccl a | $14,755,000 | – | 76,000 | +100.0% | 0.87% | – |
| ZYME | New | Zymeworks Inc | $11,924,000 | – | 410,619 | +100.0% | 0.71% | – |
| TVTX | New | Travere Therapeutics Inc | $10,604,000 | – | 437,280 | +100.0% | 0.63% | – |
| KDMN | New | Kadmon Holdings Inc | $9,113,000 | – | 1,046,312 | +100.0% | 0.54% | – |
| New | ChemoCentryx Incput | $8,649,000 | – | 505,800 | +100.0% | 0.51% | – | |
| ALXO | New | ALX Oncology Holdings Inc | $7,919,000 | – | 107,220 | +100.0% | 0.47% | – |
| SNDX | New | Syndax Pharmaceuticals Inc | $7,909,000 | – | 413,841 | +100.0% | 0.47% | – |
| ISEE | New | Iveric Bio Inc | $5,804,000 | – | 357,400 | +100.0% | 0.34% | – |
| New | Protagonist Therapeutics Inccall | $5,316,000 | – | 300,000 | +100.0% | 0.32% | – | |
| GH | New | Guardant Health Inc | $5,000,000 | – | 40,000 | +100.0% | 0.30% | – |
| New | Iveric Bio Incput | $4,146,000 | – | 255,300 | +100.0% | 0.25% | – | |
| New | Novocure Ltdcall | $3,485,000 | – | 30,000 | +100.0% | 0.21% | – | |
| New | Intercept Pharmaceuticals Incall | $2,822,000 | – | 190,000 | +100.0% | 0.17% | – | |
| FULC | New | Fulcrum Therapeutics Inc | $1,439,000 | – | 51,006 | +100.0% | 0.08% | – |
| FUSN | New | Fusion Pharmaceuticals Inc | $618,000 | – | 78,066 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.